Innocube, a bio-healthcare accelerator, announced on the 3rd that it is recruiting for the first S to B (Science to Business) Challenge to discover potential researchers and startups in the field of bio-healthcare.
Handok and Genexine will participate in this challenge together. For prospective startup teams, initial funding support and customized programs for each stage of growth are provided so that creative ideas and technologies can be commercialized.
The first stage of the S to B Challenge can be applied by prospective entrepreneurs in the bio-healthcare field, including bio/new drugs, medical devices, diagnostics, and digital healthcare, as well as startups with less than 3 years of experience.
Seed investment of around 200 million won is provided to the final selected prospective startup team, seed investment and Pre-A investment are supported to startups, and a public office and laboratory including research equipment are provided.
In addition, it is a major field of interest that can be collaborated with Handok or Genexine, such as metabolic, rare, anticancer, synthetic new drugs of new innovative therapies, immunotherapeutics, antibodies, antibody drug complexes (ADC), cell therapy, genetic difference therapy, and biopharmaceuticals such as mRNA technology. Selected companies are given priority in joint research.
In addition, services for commercialization such as technology diagnosis, commercialization consulting and mentoring, full-cycle R&D support, and industrial and investment networking are also provided to selected companies.
Applications for the S to B Challenge will be accepted through the ‘Apply Inquiry’ section of the Innocube website until April 21st, and final selection will be made after the first face-to-face evaluation and face-to-face presentation in May. For more information and inquiries about the S to B Challenge, visit the Innocube website.
Kwon So-hyun, CEO of Innocube, said, “This ‘S to B Challenge’ is a collaboration between Handok and Genexine, which are evaluated as the best example of open innovation in the field of bio-healthcare, so that ideas and technologies with potential can be commercialized. “We hope that we will be able to increase global competitiveness in the domestic bio-healthcare field and build a healthy bio-venture ecosystem through shared growth with promising researchers and startups.”
As a bio-healthcare accelerator company, Innocube discovers startups with excellent capabilities, provides initial funding, and provides infrastructure such as shared research space and research equipment. Total services are also provided so that innovative ideas and technologies of startups can be commercialized, such as project development discussions and management support.